Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Cytori Therapeutics logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Advanced Chart

Key Stats

Today's Range
$0.49
$0.59
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
12.42 million shs
Average Volume
915,302 shs
Market Capitalization
$12.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Stock News Headlines

Cytori Cell Research Institute Inc.
Checkpoint Therapeutics Inc (CKPT)
This New Rule Could Change Everything
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Sage Therapeutics Inc SAGE
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines

CYTX Stock Analysis - Frequently Asked Questions

Cytori Therapeutics Inc (NASDAQ:CYTX) announced its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

Shares of Cytori Therapeutics reverse split before market open on Thursday, May 24th 2018.The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

Last Earnings
5/14/2019
Today
8/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
CIK
1095981
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.63 million
Net Margins
-242.60%
Pretax Margin
N/A
Return on Equity
-272.70%
Return on Assets
-56.23%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
0.46
Quick Ratio
0.30

Sales & Book Value

Annual Sales
$3.67 million
Price / Sales
2.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
1.38

Miscellaneous

Outstanding Shares
22,160,000
Free Float
N/A
Market Cap
$10.70 million
Optionable
Not Optionable
Beta
1.96
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CYTX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners